Patent expiries will lead to blood disorders drugs growth
GBI report forecasts market will be worth more than US$50bn by 2016
In 2009, the global blood disorders market was worth around US$38bn, representing a cumulative annual growth rate of 8% between 2001 and 2009. By 2016, it is expected to reach US$51bn.
According to the GBI Research report, The Future of Blood Disorders – Better and More Cost-Effective Treatment Options Create Opportunities, with the imminent patent expiries in the blood disorders market the need for novel drug candidates to complete the clinical development stages successfully and reach the market is strong.
Between 2009 and 2016, most of the top-selling blockbuster drugs in the anaemia, thrombosis, haemophilia and neutropoenia market will come to the end of their patent protection. These include NovoSeven (2010), Plavix (2011), Lovenox (2012), Neupogen (2013), Epogen (2013), Procrit (2013), Kogenate (2014), Aranesp (2014) and Neulasta (2015), which together account for revenues of more than US$24bn worldwide.
The top five players control approximately 77% of the market. Amgen is current market leader with Neulasta, Aranesp, Epogen and Neupogen, accounting for 28% of the total blood disorders market. Sanofi-Aventis follows with a 22% market share, primarily due to its anticoagulant Plavix, co-marketed with BMS (Bristol-Myers Squibb), and its venous thrombosis drug Lovenox.
BMS’ third position is attributed to sales of Plavix. Ortho Biotech and Baxter are the fourth and the fifth largest players respectively, primarily due to Procrit and Advate. However, these positions are expected to change in the future, says GBI.
‘With M&A activity in the blood disorders market at a very low level, the future dominant players are expected to be those who come up with novel, safer, more efficacious and more convenient therapeutics,’ the report says.
During 2009 and the first two months of 2010, only 13 major licensing deals were signed in the global blood disorder market. However, the positive aspect of these deals is that 69% of them involve early stage discovery molecules. While 38% were signed for molecules in Phase II, 31% took place for molecules in the preclinical and discovery phase. Approximately 8% of the deals were signed for molecules in Phase III development. The approved drugs contributed to approximately 15% of the total licensing deals, while 8% involved drugs currently waiting for market approval.
